{
    "markdown": "<a id='2fc4e65a-dca4-4fee-b941-527377464b70'></a>\n\nResults in supplemental studies with NN622 will indirectly prove appropriateness of our hypothesis.\nNo additional actions for Actos and TAK-559 will be required.\n\n<a id='4ae898ee-0691-4b1b-9203-aeefe2ecf24e'></a>\n\n[Pessimistic views]\nNovo Nordisk will think another hypothesis different from ours.\nNovo Nordisk will stop development of NN622 without clarification of possible mechanisms.\nNovo Nordisk will use Actos as a positive control and get some contradictory results to ours.\nThere will be bladder tumors in a carcinogenicity study of TAK-559 without any microcrystallines or\ncalculi.\n\u2193\nThe authorities including FDA/EMEA may require that we should reconsider our hypothesis in both of\nActos and TAK-559 based on Novo Nordisk's hypothesis or find other hypotheses.\nIn worst case, when Novo Nordisk will stop its development for this reason, the regulatory authorities\nmay not allow us to sell Actos or to continue clinical studies of TAK-559 until we can clarify the\nmechanisms of the tumors.\n\n<a id='022aac50-5852-4da2-b983-74aa723d23c4'></a>\n\n[Other views]\nNovo Nordisk expect the filing for approval to be delayed by close to 2 years. If only this tumor issue does matter, 2 years until its NDA submission seem to be too long if it is set only for clarification of the mechanism. Therefore, we may guess that NN622 might have other issues in clinical trials and \"urinary bladder tumor\" is used just as a scapegoat or that Novo Nordisk virtually give up the development.\n\n<a id='1984116b-9b17-4e01-bff0-02c0f90b45c1'></a>\n\n2\n\n<a id='db58f894-106c-4018-983d-c477c619f66b'></a>\n\n2002/7/24 DSRL\n\n<a id='f9cf8e74-311b-49cc-9c61-eb0bc5760bbc'></a>\n\nConfidential - Subject to Protective Order\n\n<a id='6b974c07-4e46-445b-9564-2c6d56907b64'></a>\n\nTAK-THOMCL-00019814\nProduced in MDL on 09/14/12\n\n<a id='4befeb67-8155-409a-bd44-76e2b7e93e20'></a>\n\nSource: https://www.indupP2298-00002s.ucsf.edu/docs/zyjf0226",
    "chunks": [
        {
            "markdown": "<a id='2fc4e65a-dca4-4fee-b941-527377464b70'></a>\n\nResults in supplemental studies with NN622 will indirectly prove appropriateness of our hypothesis.\nNo additional actions for Actos and TAK-559 will be required.",
            "type": "text",
            "id": "2fc4e65a-dca4-4fee-b941-527377464b70",
            "grounding": {
                "box": {
                    "left": 0.18022596836090088,
                    "top": 0.11037886142730713,
                    "right": 0.7595250010490417,
                    "bottom": 0.1432095170021057
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='4ae898ee-0691-4b1b-9203-aeefe2ecf24e'></a>\n\n[Pessimistic views]\nNovo Nordisk will think another hypothesis different from ours.\nNovo Nordisk will stop development of NN622 without clarification of possible mechanisms.\nNovo Nordisk will use Actos as a positive control and get some contradictory results to ours.\nThere will be bladder tumors in a carcinogenicity study of TAK-559 without any microcrystallines or\ncalculi.\n\u2193\nThe authorities including FDA/EMEA may require that we should reconsider our hypothesis in both of\nActos and TAK-559 based on Novo Nordisk's hypothesis or find other hypotheses.\nIn worst case, when Novo Nordisk will stop its development for this reason, the regulatory authorities\nmay not allow us to sell Actos or to continue clinical studies of TAK-559 until we can clarify the\nmechanisms of the tumors.",
            "type": "text",
            "id": "4ae898ee-0691-4b1b-9203-aeefe2ecf24e",
            "grounding": {
                "box": {
                    "left": 0.18052172660827637,
                    "top": 0.15673068165779114,
                    "right": 0.7774955630302429,
                    "bottom": 0.34516391158103943
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='022aac50-5852-4da2-b983-74aa723d23c4'></a>\n\n[Other views]\nNovo Nordisk expect the filing for approval to be delayed by close to 2 years. If only this tumor issue does matter, 2 years until its NDA submission seem to be too long if it is set only for clarification of the mechanism. Therefore, we may guess that NN622 might have other issues in clinical trials and \"urinary bladder tumor\" is used just as a scapegoat or that Novo Nordisk virtually give up the development.",
            "type": "text",
            "id": "022aac50-5852-4da2-b983-74aa723d23c4",
            "grounding": {
                "box": {
                    "left": 0.181325763463974,
                    "top": 0.3586517870426178,
                    "right": 0.7764884233474731,
                    "bottom": 0.45415011048316956
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='1984116b-9b17-4e01-bff0-02c0f90b45c1'></a>\n\n2",
            "type": "marginalia",
            "id": "1984116b-9b17-4e01-bff0-02c0f90b45c1",
            "grounding": {
                "box": {
                    "left": 0.47208714485168457,
                    "top": 0.7981085181236267,
                    "right": 0.49017953872680664,
                    "bottom": 0.814003050327301
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='db58f894-106c-4018-983d-c477c619f66b'></a>\n\n2002/7/24 DSRL",
            "type": "text",
            "id": "db58f894-106c-4018-983d-c477c619f66b",
            "grounding": {
                "box": {
                    "left": 0.6790519952774048,
                    "top": 0.7961309552192688,
                    "right": 0.7778421640396118,
                    "bottom": 0.8143324255943298
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='f9cf8e74-311b-49cc-9c61-eb0bc5760bbc'></a>\n\nConfidential - Subject to Protective Order",
            "type": "marginalia",
            "id": "f9cf8e74-311b-49cc-9c61-eb0bc5760bbc",
            "grounding": {
                "box": {
                    "left": 0.07763693481683731,
                    "top": 0.8566797375679016,
                    "right": 0.3256588876247406,
                    "bottom": 0.8748344779014587
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='6b974c07-4e46-445b-9564-2c6d56907b64'></a>\n\nTAK-THOMCL-00019814\nProduced in MDL on 09/14/12",
            "type": "text",
            "id": "6b974c07-4e46-445b-9564-2c6d56907b64",
            "grounding": {
                "box": {
                    "left": 0.7151573300361633,
                    "top": 0.8569083213806152,
                    "right": 0.9089102149009705,
                    "bottom": 0.8893920183181763
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='4befeb67-8155-409a-bd44-76e2b7e93e20'></a>\n\nSource: https://www.indupP2298-00002s.ucsf.edu/docs/zyjf0226",
            "type": "marginalia",
            "id": "4befeb67-8155-409a-bd44-76e2b7e93e20",
            "grounding": {
                "box": {
                    "left": 0.22081983089447021,
                    "top": 0.978151261806488,
                    "right": 0.7800631523132324,
                    "bottom": 0.9999949336051941
                },
                "page": 0
            }
        }
    ],
    "splits": [
        {
            "class": "full",
            "identifier": "full",
            "pages": [
                0
            ],
            "markdown": "<a id='2fc4e65a-dca4-4fee-b941-527377464b70'></a>\n\nResults in supplemental studies with NN622 will indirectly prove appropriateness of our hypothesis.\nNo additional actions for Actos and TAK-559 will be required.\n\n<a id='4ae898ee-0691-4b1b-9203-aeefe2ecf24e'></a>\n\n[Pessimistic views]\nNovo Nordisk will think another hypothesis different from ours.\nNovo Nordisk will stop development of NN622 without clarification of possible mechanisms.\nNovo Nordisk will use Actos as a positive control and get some contradictory results to ours.\nThere will be bladder tumors in a carcinogenicity study of TAK-559 without any microcrystallines or\ncalculi.\n\u2193\nThe authorities including FDA/EMEA may require that we should reconsider our hypothesis in both of\nActos and TAK-559 based on Novo Nordisk's hypothesis or find other hypotheses.\nIn worst case, when Novo Nordisk will stop its development for this reason, the regulatory authorities\nmay not allow us to sell Actos or to continue clinical studies of TAK-559 until we can clarify the\nmechanisms of the tumors.\n\n<a id='022aac50-5852-4da2-b983-74aa723d23c4'></a>\n\n[Other views]\nNovo Nordisk expect the filing for approval to be delayed by close to 2 years. If only this tumor issue does matter, 2 years until its NDA submission seem to be too long if it is set only for clarification of the mechanism. Therefore, we may guess that NN622 might have other issues in clinical trials and \"urinary bladder tumor\" is used just as a scapegoat or that Novo Nordisk virtually give up the development.\n\n<a id='1984116b-9b17-4e01-bff0-02c0f90b45c1'></a>\n\n2\n\n<a id='db58f894-106c-4018-983d-c477c619f66b'></a>\n\n2002/7/24 DSRL\n\n<a id='f9cf8e74-311b-49cc-9c61-eb0bc5760bbc'></a>\n\nConfidential - Subject to Protective Order\n\n<a id='6b974c07-4e46-445b-9564-2c6d56907b64'></a>\n\nTAK-THOMCL-00019814\nProduced in MDL on 09/14/12\n\n<a id='4befeb67-8155-409a-bd44-76e2b7e93e20'></a>\n\nSource: https://www.indupP2298-00002s.ucsf.edu/docs/zyjf0226",
            "chunks": [
                "2fc4e65a-dca4-4fee-b941-527377464b70",
                "4ae898ee-0691-4b1b-9203-aeefe2ecf24e",
                "022aac50-5852-4da2-b983-74aa723d23c4",
                "1984116b-9b17-4e01-bff0-02c0f90b45c1",
                "db58f894-106c-4018-983d-c477c619f66b",
                "f9cf8e74-311b-49cc-9c61-eb0bc5760bbc",
                "6b974c07-4e46-445b-9564-2c6d56907b64",
                "4befeb67-8155-409a-bd44-76e2b7e93e20"
            ]
        }
    ],
    "grounding": {
        "2fc4e65a-dca4-4fee-b941-527377464b70": {
            "box": {
                "left": 0.18022596836090088,
                "top": 0.11037886142730713,
                "right": 0.7595250010490417,
                "bottom": 0.1432095170021057
            },
            "page": 0,
            "type": "chunkText"
        },
        "4ae898ee-0691-4b1b-9203-aeefe2ecf24e": {
            "box": {
                "left": 0.18052172660827637,
                "top": 0.15673068165779114,
                "right": 0.7774955630302429,
                "bottom": 0.34516391158103943
            },
            "page": 0,
            "type": "chunkText"
        },
        "022aac50-5852-4da2-b983-74aa723d23c4": {
            "box": {
                "left": 0.181325763463974,
                "top": 0.3586517870426178,
                "right": 0.7764884233474731,
                "bottom": 0.45415011048316956
            },
            "page": 0,
            "type": "chunkText"
        },
        "1984116b-9b17-4e01-bff0-02c0f90b45c1": {
            "box": {
                "left": 0.47208714485168457,
                "top": 0.7981085181236267,
                "right": 0.49017953872680664,
                "bottom": 0.814003050327301
            },
            "page": 0,
            "type": "chunkMarginalia"
        },
        "db58f894-106c-4018-983d-c477c619f66b": {
            "box": {
                "left": 0.6790519952774048,
                "top": 0.7961309552192688,
                "right": 0.7778421640396118,
                "bottom": 0.8143324255943298
            },
            "page": 0,
            "type": "chunkText"
        },
        "f9cf8e74-311b-49cc-9c61-eb0bc5760bbc": {
            "box": {
                "left": 0.07763693481683731,
                "top": 0.8566797375679016,
                "right": 0.3256588876247406,
                "bottom": 0.8748344779014587
            },
            "page": 0,
            "type": "chunkMarginalia"
        },
        "6b974c07-4e46-445b-9564-2c6d56907b64": {
            "box": {
                "left": 0.7151573300361633,
                "top": 0.8569083213806152,
                "right": 0.9089102149009705,
                "bottom": 0.8893920183181763
            },
            "page": 0,
            "type": "chunkText"
        },
        "4befeb67-8155-409a-bd44-76e2b7e93e20": {
            "box": {
                "left": 0.22081983089447021,
                "top": 0.978151261806488,
                "right": 0.7800631523132324,
                "bottom": 0.9999949336051941
            },
            "page": 0,
            "type": "chunkMarginalia"
        }
    },
    "metadata": {
        "filename": "zyjf0226_2.png",
        "org_id": null,
        "page_count": 1,
        "duration_ms": 6255,
        "credit_usage": 3.0,
        "job_id": "kvogwbwwqk9ur39xw8qopsmrq",
        "version": "dpt-2-20250919"
    }
}